Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 535-553 , December 2007

Cannabinoid-1 receptor antagonists in type-2 diabetes

  • André J. Scheen, MD, PhD (Professor, Doctor)

      Affiliations

    • Corresponding Author InformationTel.: +32 43667238; Fax: +32 43667068.

References 

  1. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Society for the Study of Diabetes (EASD) . Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. European Heart Journal. 2007;28:88–136
  2. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults . Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation. 2002;106:3143–3421
  3. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110:2952–2967
  4. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887
  5. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–880
  6. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs. 2003;63:1165–1184
  7. Lee M, Aronne LJ. Weight management for type-2 diabetes mellitus: global cardiovascular risk reduction. American Journal of Cardiology. 2007;99(supplementary):68B–79B
  8. American Diabetes Association . Clinical Practice Recommendations 2005. Diabetes Care. 2005;28(supplementary 1):S1–S79
  9. IDF Clinical Guidelines Task force . Global Guideline for Type-2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Medicine. 2006;23:579–593
  10. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. Journal of the American College of Nutrition. 2003;22:331–339
  11. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898–918
  12. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology. 2004;141:765–774
  13. Howlett AC, Breivogel CS, Childers SR, et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47(supplementary 1):345–358
  14. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews. 2006;27:73–100
  15. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews. Neuroscience. 2003;4:873–884
  16. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nature Reviews. Drug Discovery. 2004;3:771–784
  17. Mendizabal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology. 2007;151:427–440
  18. Xie S, Furjanic MA, Ferrara JJ, et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1-receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use. Journal of Clinical Pharmacy and Therapeutics. 2007;32:209–231
  19. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006;114:974–984
  20. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience. 2005;8:585–589
  21. Carai MA, Colombo G, Maccioni P, et al. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Reviews. 2006;12:91–99
  22. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation. 2003;112:423–431
  23. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Journal of the American College of Cardiology. 2006;47:1919–1926
  24. Woods AC. Role of endocannabinoid system in regulating cardiovascular and metabolic risk factors. American Journal of Medicine. 2007;120(supplementary 3A):S19–S25
  25. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes & Metabolism. 2007;33:85–95
  26. Kogan NM, Mechoulam R. The chemistry of endocannabinoids. Journal of Endocrinological Investigation. 2006;29(supplementary to Ndeg 3):3–14
  27. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics. 1997;74:129–180
  28. McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signaling: a focus on endocannabinoids. Prostaglandins Leukotrienes and Essential Fatty Acids. 2002;66:161–171
  29. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. The Journal of Pharmacological and Experimental Therapeutics. 2001;298:7–14
  30. Harrold JA, Williams G. The cannabinoid system: A role in both the homeostatic and hedonic control of eating?. British Journal of Nutrition. 2003;90:729–734
  31. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology. 2003;63:908–914
  32. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews. 2005;6:13–21
  33. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. Journal of Molecular Medicine. 2005;83:944–954
  34. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation. 2005;115:1298–1305
  35. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity and Related Metabolic Disorders. 2005;29:183–187
  36. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, et al. Cannabinoid receptor regulates Ca(2+) signals and insulin secretion in pancreatic beta-cells. Cell Calcium. 2006;39:155–162
  37. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3171–3180
  38. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sciences. 2005;76:1307–1324
  39. Salamone JD, McLaughlin PJ, Sink K, et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behaviour and food aversions. Physiology & Behavior. 2007;91:383–388
  40. Rinaldi-Carmona M, Barth F, Heulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters. 1994;350:240–244
  41. Dutta AK, Sard H, Ryan W, et al. The synthesis and pharmacological evaluation of the cannabinoid antagonist SR141716A. Medicinal Chemistry Research. 1994;5:54–62
  42. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opinion on Investigational Drugs. 2006;15:307–315
  43. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews. 2006;4:CD006162
  44. Lange JH, Coolen HK, van Stuivenberg HH, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry. 2004;47:627–643
  45. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/acomplia/acomplia.htm
  46. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews. 2007;(3):CD005353
  47. Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular Pharmacology. 2007;71:1445–1456
  48. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolic Disorders. 2004;28:640–648
  49. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2003;284:R345–R353
  50. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. The Journal of Neuroscience. 2002;22:9612–9617
  51. Schwabbe RF. Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. Hepatology. 2005;42:959–961
  52. Luyckx FH, Scheen AJ, Lefèbvre PJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes & Metabolism. 2000;26:98–106
  53. Medina J, Fernandez-Salazar LI, Garcia-Buey L, et al. Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. Diabetes Care. 2004;27:2057–2066
  54. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676
  55. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity. 2007;15:837–845
  56. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal. 2005;19:1567–1569
  57. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism. 2007;18:27–37
  58. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843
  59. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–3060
  60. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity. 2007;31:692–699
  61. Sipe J, Waalen J, Gerber A, et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity. 2005;29:755–759
  62. Aberle J, Fedderwitz I, Klages N, et al. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Hormone and Metabolic Research. 2007;39:395–397
  63. Russo P, Strazzullo P, Cappuccio FP, et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. The Journal of Clinical Endocrinology and Metabolism. 2007;92:2382–2386
  64. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  65. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. The Journal of the American Medical Association. 2006;295:761–775
  66. Després JP, Golay A, Sjöström L. Rimonabant in Obesity-Lipids Study Group. Effects on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicne. 2005;353:2121–2134
  67. Després JP, Van Gaal L, Scheen A, et al. Rimonabant improves cardiometabolic risk factors in overweight/obese patients irrespective of treatment with statins: pooled data from the RIO program. (Abstract) Atherosclerosis. 2006;7(supplementary):329
  68. Ruilope LM, Després JP, Scheen A et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled Rimonabant In Obesity (RIO) study results. Journal of Hypertension, (in press).
  69. Pi-Sunyer F-X, Després J-P, Scheen A, et al. Improvement of metabolic effects with rimonabant beyond the effect attributable to weight loss alone: pooled one year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorders) program (Abstract). Journal of the American College of Cardiology. 2006;47(supplementary A):362-A
  70. Scheen AJ, Finer N, Hollander P, et al., for the RIO-Diabetes Study Group  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–1672
  71. Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?. Diabetes & Metabolism. 2007;33:3–12
  72. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–1972
  73. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Archives of Internal Medicine. 2004;164:395–404
  74. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–77
  75. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine. 2003;348:383–393
  76. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical Research Ed). 2000;321:405–412
  77. Iranmanesh A, Rosenstock J, Hollander P, SERENADE-Study-Group , et al. SERENADE : Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naïve patients with type 2 diabetes. (Abstract) Diabetic Medicine. 2006;23(supplementary 4):230
  78. Yk-Järvinen H. Fat in the liver and insulin resistance. Annals of Medicine. 2005;37:347–356
  79. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. American Journal of Medicine. 2005;118:939–947
  80. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499–1504
  81. CRESCENDO Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes. Available from: http://www.clinicaltrials.gov/ct/show/NCT00263042?order = 2. [Accessed February 1, 2007].
  82. Van Gaal L, Pi-Sunyer X, Després JP et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the RIO program. Diabetes Care (in press).
  83. Food and Drug Administration. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-00-index.htm.

PII: S1521-690X(07)00082-6

doi: 10.1016/j.beem.2007.08.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 535-553 , December 2007

Article Tools

* Image Usage & Resolution